Table of Contents Author Guidelines Submit a Manuscript
Corrigendum
Letter to the Editor
Research Article
BioMed Research International
Volume 2017, Article ID 5359434, 2 pages
https://doi.org/10.1155/2017/5359434
Letter to the Editor

Response to: Comment on “Detecting Key Genes Regulated by miRNAs in Dysfunctional Crosstalk Pathway of Myasthenia Gravis”

1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, China
2Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China

Correspondence should be addressed to Lihua Wang; moc.361@112hlgnaw

Received 4 January 2017; Accepted 20 February 2017; Published 14 August 2017

Academic Editor: Rituraj Purohit

Copyright © 2017 Yuze Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Le Panse, “Comment on ‘detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis’,” BioMed Research International, vol. 2017, Article ID 6950308, 1 page, 2017. View at Publisher · View at Google Scholar
  2. Y. Cao, J. Wang, H. Zhang et al., “Detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis,” BioMed Research International, vol. 2015, Article ID 724715, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Cao, J. Wang, H. Zhang et al., “Corrigendum to ‘detecting key genes regulated by miRNAs in dysfunctional crosstalk pathway of myasthenia gravis’,” BioMed Research International, vol. 2017, Article ID 9281250, 1 page, 2017. View at Publisher · View at Google Scholar
  4. Y.-M. Shiao, C.-C. Lee, Y.-H. Hsu et al., “Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia,” Journal of Neuroimmunology, vol. 221, no. 1-2, pp. 101–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Zhang, J. Guo, H. Li et al., “Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis,” Journal of Molecular Neuroscience, vol. 50, no. 2, pp. 317–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Feferman, P. K. Maiti, S. Berrih-Aknin et al., “Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis,” Journal of Immunology, vol. 174, no. 9, pp. 5324–5331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Nancy and S. Berrih-Aknin, “Differential estrogen receptor expression in autoimmune myasthenia gravis,” Endocrinology, vol. 146, no. 5, pp. 2345–2353, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Colombara, V. Antonini, A. P. Riviera et al., “Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells,” Journal of Immunology, vol. 175, no. 10, pp. 7021–7028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. P. Sieb, “Myasthenia gravis: an update for the clinician,” Clinical and Experimental Immunology, vol. 175, no. 3, pp. 408–418, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. B. M. Conti-Fine, M. Milani, and H. J. Kaminski, “Myasthenia gravis: past, present, and future,” Journal of Clinical Investigation, vol. 116, no. 11, pp. 2843–2854, 2006. View at Publisher · View at Google Scholar · View at Scopus